Effect of anti-IgE therapy on atopic eczema symptoms in patients with asthma

Abstract

RATIONALE: To compare severity of atopic dermatitis based on our institution's clinical scoring system for atopic dermatitis (CSAD) with ECP and IgE levels. METHODS: Data on 20 patients with AD was collected. The severity of disease was scored using CSAD, which includes assessment of three items (1) subjective score (quality of life), (2) objective score (type and extent of lesions) and (3) exacerbation score (based on use of rescue medication). AD was classified into four grades, mild (I), moderate (II) severe (III), and extremely severe (IV). Severity was compared with four levels of ECP level I(1-20), level II(21-40), level III(41-60) and level IV(>60).Comparison was also done with four levels of serum IgE. Level I (100-1000)), level II (>1000-5000), level III (>5000-10000) and level IV (>10,000). RESULTS: (i) 3 patients were placed in mild, 6 in moderate, 6 in severe and 5 in extremely severe categories. (ii) 6 patients had ECP at level I, 4 at level II, 7 at level III and 3 were placed in level IV category. (iii) 3 patients had serum IgE at level I, 4 at level II,7 at level III and 6 were placed in level IV category.(iv) There was no correlation between the clinical severity score , ECP and serum IgE levels. CONCLUSIONS: Our data indicate that basic clinical scoring remains a most effective method of recording skin activity in AD. A larger patient sample may needed to clarify the relation between severity of atopic dermatitis, ECP and serum IgE 416 Is Maternal History of Asthma, Atopic Dermatitis, Food Aller-

A review of omalizumab for the management of severe asthma

“… 75 As early as 2005, several case series and reports have documented positive effects of omalizumab in treating patients with atopic dermatitis and comorbid asthma. 76 , 77 Efficacies in improving patient clinical outcomes and reducing free IgE levels have subsequently been broadly reported and confirmed in various RCTs, prospective open-label studies, as well as retrospective studies. 78 – 82 However, omalizumab is not yet approved for the treatment of atopic dermatitis despite the positive results observed.…”